#3008 SERENDIPITY OF SGLT2 INHIBITION – DIABETIC AND NON DIABETIC CKD
نویسندگان
چکیده
Abstract Background and Aims Ever since their therapeutic introduction, SGLT2 inhibition class of medicaments did impress physicians related fields, nephrologists, internal medicine doctors, endocrinologists etc. Their natriuretic glucoretic effects besides lowering the plasma glucose does produce a important effect on intraglomerular pressure, this became an added value strong point to recommend these drugs all CKD population irregardles main cause disease. Method Observational retrospective study 125 patients, three groups: G1 50 pt with diabetic nephropathy treated empagliflozine vs control group G2 other agents, G3 25 nondiabetic proteinuria SGLT2i. Inclusion criteria was T2D for G2, patients G3. Patients T1D eGFR > 20 where excluded. Intervention - SGLT2i started, median follow up 18 months. We followed four periods creatinine levels, 24 hour in g/24 h, HbA1c, cholesterol level, BMI. Results In our showed decrease average – 811 mg/24 serum increase first months it get back baseline afterwards, increased + 15.44 ml/min; HbA1c decreased -1.41%, reduction BMI 0.9 kg/m2 LDL -1.11 mmol/l. results 121 hours, drop 3.3 ml/min, HbA1C 1.45 %, 0.3 mmol/l level 0.8 kg/m2; without but different causes where: 690 proteinuria, 14.4 eGFR, NA, we have 2 cases that experienced hypoglycemic symptoms, both them improved dose reduction, registered Conclusion observation month remarkable improve kidney function tests, benefits were noted such as optimal glycemic control, total body significant reduce weight expressed Treatment present safe efficient treatment modality proteinuria.
منابع مشابه
SGLT2 Inhibitors and the Diabetic Kidney.
Diabetic nephropathy (DN) is the most common cause of end-stage renal disease worldwide. Blood glucose and blood pressure control reduce the risk of developing this complication; however, once DN is established, it is only possible to slow progression. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, the most recent glucose-lowering oral agents, may have the potential to exert nephroprotectio...
متن کاملInhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose‐induced oxidative stress in type 1 diabetic mice
It is unclear whether the improvement in diabetic nephropathy by sodium glucose cotransporter 2 (SGLT2) inhibitors is caused by a direct effect on SGLT2 or by the improvement in hyperglycemia. Here, we investigated the effect of dapagliflozin on early-stage diabetic nephropathy using a mouse model of type 1 diabetes and murine proximal tubular epithelial cells. Eight-week-old Akita mice were tr...
متن کاملCarpal Tunnel Release in Diabetic and Non-Diabetic Patients
Background: Carpal tunnel syndrome (CTS) is a compression neuropathy that causes paresthesia, pain or numbness in the territory of median nerve. The aim of this study is to compare the open surgery outcome and patients` satisfaction in carpal tunnel syndrome among diabetic and non-diabetic patients. Methods: In a retrospective cohort study from April 2011 to June 2012, patients suffered from ca...
متن کاملSupervised Exercise Patterns among Diabetic and Non-diabetic Portuguese Adults
Background. Physical activity (PA) is a keystone of diabetes management, but although self-exercise is beneficial, supervised exercise (SE), adapted to individual characteristics, and is more effective. Objectives. The main research goal is to compare SE patterns among diabetic and non-diabetic Portuguese adults. Methods. A total of 484 participants (85 diabetics, 399 non-diabetics), aged 41-...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nephrology Dialysis Transplantation
سال: 2023
ISSN: ['1460-2385', '0931-0509']
DOI: https://doi.org/10.1093/ndt/gfad063d_3008